Search results
Results From The WOW.Com Content Network
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. [ 2 ] [ 3 ] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado .
Jennifer Doudna was born February 19, 1964, in Washington, D.C., as the daughter of Dorothy Jane (Williams) and Martin Kirk Doudna. [2][17] Her father received his PhD in English literature from the University of Michigan, and her mother held a master's degree in education. [6][7] When Doudna was seven years old, the family moved to Hawaii so ...
Market forces rained on the parade of Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders today, when the analysts...
James Mullen (CEO) James C. “Jim” Mullen (born ca. 1958) is an American business executive. He is the executive chairman at genome editing company Editas Medicine since 2018, where he also served as CEO between 2021 and 2022. [1][2][3] He was formerly the president and CEO of Biogen Idec until he retired effective June 8, 2010. [4]
After another solid quarter of progress, the genome-editing company looks forward to a phase 1/2 study for its revolutionary CRISPR medicine. Editas Medicine Prepares to Make History With EDIT-101 ...
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
J. Keith Joung is an American pathologist and molecular biologist who holds the Robert B. Colvin Endowed Chair in Pathology [1] at Massachusetts General Hospital and is Professor of Pathology at Harvard Medical School. [2] He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive ...
Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).